{"page_content": "Introduction COVID-19 Response\n3  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nHealthy People Healthy Society Healthy Planet A Healthy Amgen Appendix\nAmgen focuses on areas of high unmet medical need \nand leverages its expertise to strive for solutions that \nimprove health outcomes and dramatically improve \npeople\u2019s lives  . A biotechnology pioneer since 1980, Amgen \nhas grown to be one of the world\u2019s leading independent \nbiotechnology companies, has reached millions of patients \naround the world with its medicines, and is developing a \npipeline of innovative medicines  .\nWe focus our research in three therapeutic areas: \ninflammation, oncology, and general medicine. \nOur medicines typically address diseases for which there \nare limited treatment options or provide a viable alternative \nto those treatments that are otherwise available  . Amgen is \nalso a leader in developing and manufacturing biosimilars \n(medications that are biologically similar to existing biologic \ntreatments), which have the potential to offer more affordable, \nlife-altering treatment options  . Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, \nand delivering innovative human therapeutics. This approach begins by using tools such as advanced human genetics to unravel the complexities \nof disease and understand the fundamentals of human biology. ABOUT AMGEN\nOUR BELIEF \u2014\nand the core of our strategy\u2014 \nis that innovative, highly \ndifferentiated medicines that \nprovide large clinical benefits in \naddressing serious diseases are \nmedicines that will not only help \npatients, but also help reduce the \nsocial and economic burden \nof disease on society today  . ", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 2, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}